Lipid-lowering therapy: modern possibilities and real clinical practice
Aim. To monitor the scope and effectiveness of lipid-lowering therapy (LLT) in the out- and inpatient settings among people hospitalized at the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. Retrospective analysis of randomly selected case records for Apri...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2022-09-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408133779161088 |
|---|---|
| author | A. V. Blokhina A. I. Ershova A. N. Meshkov N. M. Akhmedzhanov A. A. Ivanova K. A. Guseinova S. A. Smetnev O. A. Litinskaya S. A. Boytsov A. M. Drapkina |
| author_facet | A. V. Blokhina A. I. Ershova A. N. Meshkov N. M. Akhmedzhanov A. A. Ivanova K. A. Guseinova S. A. Smetnev O. A. Litinskaya S. A. Boytsov A. M. Drapkina |
| author_sort | A. V. Blokhina |
| collection | DOAJ |
| description | Aim. To monitor the scope and effectiveness of lipid-lowering therapy (LLT) in the out- and inpatient settings among people hospitalized at the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. Retrospective analysis of randomly selected case records for April-May 2012, 2015 and 2022 (n=658).Results. From 2012 to 2022, the proportion of outpatients taking statins increased as follows: from 28,8 to 60,4% (from 22,2 to 73,3% for high cardiovascular risk (CVR) and from 34,8 to 91,7% for very high CVR). Patients with very high CVR were significantly more likely to be prescribed high-intensity statin therapy (from 3,8 to 45,8%). Inpatients with high CVR were prescribed statins less often (74,3%) than patients with very high CVR (93,6%). In 2022, compared to 2015, the proportion of inpatients who received combined LLT increased as follows — 8,9 vs 0,5% (p< 0,001). Target low-density lipoprotein cholesterol <1,4 mmol/l in 2022 was achieved in 18,2 and 13,6% of outpatients with high and very high CVR, respectively.Conclusion. Despite increase in the frequency of prescribing and the intensity of statin therapy, by 2022 there remains a large proportion of patients with high and very high CVR who do not receive adequate LLT, which allows them to achieve the target low-density lipoprotein cholesterol. It is important to note that modern LLT provides great opportunities for the implementation of clinical guidelines in practice. |
| format | Article |
| id | doaj-art-bb0a42bdcc204f20860bdbdc6f6a34f3 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2022-09-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-bb0a42bdcc204f20860bdbdc6f6a34f32025-08-20T03:35:51Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252022-09-0121810.15829/1728-8800-2022-33692514Lipid-lowering therapy: modern possibilities and real clinical practiceA. V. Blokhina0A. I. Ershova1A. N. Meshkov2N. M. Akhmedzhanov3A. A. Ivanova4K. A. Guseinova5S. A. Smetnev6O. A. Litinskaya7S. A. Boytsov8A. M. Drapkina9ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииI. M. Sechenov First Moscow State Medical UniversityФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииE. I. Chazov National Medical Research Center of CardiologyNational Medical Research Center for Therapy and Preventive MedicineAim. To monitor the scope and effectiveness of lipid-lowering therapy (LLT) in the out- and inpatient settings among people hospitalized at the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. Retrospective analysis of randomly selected case records for April-May 2012, 2015 and 2022 (n=658).Results. From 2012 to 2022, the proportion of outpatients taking statins increased as follows: from 28,8 to 60,4% (from 22,2 to 73,3% for high cardiovascular risk (CVR) and from 34,8 to 91,7% for very high CVR). Patients with very high CVR were significantly more likely to be prescribed high-intensity statin therapy (from 3,8 to 45,8%). Inpatients with high CVR were prescribed statins less often (74,3%) than patients with very high CVR (93,6%). In 2022, compared to 2015, the proportion of inpatients who received combined LLT increased as follows — 8,9 vs 0,5% (p< 0,001). Target low-density lipoprotein cholesterol <1,4 mmol/l in 2022 was achieved in 18,2 and 13,6% of outpatients with high and very high CVR, respectively.Conclusion. Despite increase in the frequency of prescribing and the intensity of statin therapy, by 2022 there remains a large proportion of patients with high and very high CVR who do not receive adequate LLT, which allows them to achieve the target low-density lipoprotein cholesterol. It is important to note that modern LLT provides great opportunities for the implementation of clinical guidelines in practice.https://cardiovascular.elpub.ru/jour/article/view/3369lipid-lowering therapystatinsatorvastatinrosuvastatinoutpatient carelow-density lipoprotein cholesterolcardiovascular riskhyperlipidemia |
| spellingShingle | A. V. Blokhina A. I. Ershova A. N. Meshkov N. M. Akhmedzhanov A. A. Ivanova K. A. Guseinova S. A. Smetnev O. A. Litinskaya S. A. Boytsov A. M. Drapkina Lipid-lowering therapy: modern possibilities and real clinical practice Кардиоваскулярная терапия и профилактика lipid-lowering therapy statins atorvastatin rosuvastatin outpatient care low-density lipoprotein cholesterol cardiovascular risk hyperlipidemia |
| title | Lipid-lowering therapy: modern possibilities and real clinical practice |
| title_full | Lipid-lowering therapy: modern possibilities and real clinical practice |
| title_fullStr | Lipid-lowering therapy: modern possibilities and real clinical practice |
| title_full_unstemmed | Lipid-lowering therapy: modern possibilities and real clinical practice |
| title_short | Lipid-lowering therapy: modern possibilities and real clinical practice |
| title_sort | lipid lowering therapy modern possibilities and real clinical practice |
| topic | lipid-lowering therapy statins atorvastatin rosuvastatin outpatient care low-density lipoprotein cholesterol cardiovascular risk hyperlipidemia |
| url | https://cardiovascular.elpub.ru/jour/article/view/3369 |
| work_keys_str_mv | AT avblokhina lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT aiershova lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT anmeshkov lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT nmakhmedzhanov lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT aaivanova lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT kaguseinova lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT sasmetnev lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT oalitinskaya lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT saboytsov lipidloweringtherapymodernpossibilitiesandrealclinicalpractice AT amdrapkina lipidloweringtherapymodernpossibilitiesandrealclinicalpractice |